005690.KS Pharmicell Co., Ltd.
KSCHealthcareAs of 2026-08-18 07:58
Why 005690.KS matters now
Pharmicell Co., Ltd. (005690.KS) is a Korea stock in Healthcare. The latest InvestLog snapshot shows ₩11,910.00 with -0.08% on the session and ₩714.65B in market capitalization.
Valuation context is available even where detailed statement rows are sparse: InvestLog currently shows P/E 15.35, gross margin 44.1%, and operating margin 32.4%.
Valuation
P/E (TTM)
15.35
PEG
—
P/B
4.98
P/S
5.26
EV/EBITDA
15.43
DCF Value
—
FCF Yield
3.7%
Div Yield
0.4%
Margins & Returns
Gross Margin
44.1%
Operating Margin
32.4%
Net Margin
34.3%
ROE
36.5%
ROA
25.3%
ROIC
25.1%
Listing Info
Market
Korea
Exchange
KSC
Currency
KRW
Sector
Healthcare
Industry
Biotechnology
Country
KR
Headquartered in Seoul, South Korea, Pharmicell Co., Ltd. is a biopharmaceutical company established in 2002, actively developing and marketing stem cell treatments across South Korea and globally. The firm operates through two primary segments: Biopharmaceutical Business and Biochemical Business. Its flagship approved product, Cellgram_AMI, leverages a patient's own bone marrow-derived mesenchymal stem cells to enhance heart pumping capacity (ejection fraction) in individuals who have suffered acute myocardial infarction and subsequently undergone coronary angioplasty. Beyond this, Pharmicell is actively progressing several pipeline candidates, including Cellgram_LC for liver ailments, Cellgram_ED targeting impotence, Cellgram_DC for cancer treatment, and Hearticellgram_AM for various cardiac conditions. In its Biochemical division, the company produces crucial intermediates for pharmaceutical raw materials, such as nucleosides, mPEGs, and HDP-tosylate, alongside manufacturing specialized industrial materials like low dielectric constant substances and eco-friendly flame retardants. Furthermore, Pharmicell operates "Twelve," a dedicated stem cell bank, and formulates cosmetics utilizing stem cell culture media.